AAAAAA

   
Results: 1-7 |
Results: 7
Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4
Authors: Glazer, NB Cheatham, WW
Citation: Nb. Glazer et Ww. Cheatham, Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4, BR MED J, 322(7280), 2001, pp. 235-236
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
Authors: Rosenblatt, S Miskin, B Glazer, NB Prince, MJ Robertson, KE
Citation: S. Rosenblatt et al., The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus, CORON ART D, 12(5), 2001, pp. 413-423
Thiazolidinedione side effects comparison elicits clarification
Authors: Glazer, NB Wishner, W
Citation: Nb. Glazer et W. Wishner, Thiazolidinedione side effects comparison elicits clarification, FORMULARY, 35(11), 2000, pp. 914-914
Good publication practice guidelines for pharmaceutical companies
Authors: Wager, E Tumas, JA Field, EA Glazer, NB Schulz, G Grossman, L
Citation: E. Wager et al., Good publication practice guidelines for pharmaceutical companies, CAN J GASTR, 14(9), 2000, pp. 749-749
The latest developments in insulin injection devices
Authors: Robertson, KE Glazer, NB Campbell, RK
Citation: Ke. Robertson et al., The latest developments in insulin injection devices, DIABET EDUC, 26(1), 2000, pp. 135
Improving the conduct and reporting of clinical trials
Authors: Wager, E Tumas, JA Field, EA Glazer, NB Schulz, G Grossman, L
Citation: E. Wager et al., Improving the conduct and reporting of clinical trials, J AM MED A, 283(21), 2000, pp. 2788-2789
Safety of insulin lispro: Pooled data from clinical trials
Authors: Glazer, NB Zalani, S Anderson, JH Bastyr, ED
Citation: Nb. Glazer et al., Safety of insulin lispro: Pooled data from clinical trials, AM J HEAL S, 56(6), 1999, pp. 542-547
Risultati: 1-7 |